MarketPulse

10b5-1 trading plan

6 articles
The Motley FoolThe Motley Fool··Sarah Sidlow

Ardelyx CEO Sells $243K in Stock as Biotech Eyes Recovery

Ardelyx CEO sells $243K in shares via routine trading plan as company improves operationally; analysts see 170% upside potential.
ARDXclass action lawsuitbiotech
The Motley FoolThe Motley Fool··Seena Hassouna

Adaptive Biotech President Sells $1.2M in Stock, But Bullish Stance Remains Intact

Adaptive Biotechnologies' president sold $1.21M in shares via pre-planned transaction, yet retains substantial holdings. Stock up 51% annually as core MRD business surges.
ADPTbiotechnologyinsider sale
The Motley FoolThe Motley Fool··Seena Hassouna

Five9 President's $147K Stock Sale Driven by Taxes, Not Concern

Five9 President sold $147K in shares; 59% was mandatory tax withholding from RSU vesting, 41% followed a pre-planned trading schedule. He retains $5.23M worth of stock.
FIVNSaaSinsider trading
The Motley FoolThe Motley Fool··Seena Hassouna

Trupanion CFO Completes Systematic Stock Divestment With Final Share Sale

Trupanion CFO completed nine-month systematic stock divestment of 19,859 shares via pre-planned 10b5-1 trading arrangement, signaling financial diversification rather than company concerns.
TRUPinsider trading10b5-1 trading plan
The Motley FoolThe Motley Fool··Jonathan Ponciano

Slide Insurance Posts $444M Profit on Strong Revenue Growth; Insider Trims Position

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.
SLDEfinancial resultsrevenue growth
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics CMO Completes Share Divestiture Amid Positive Clinical Momentum

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.
MAZEIPOclinical trials